Kevin Rakin

Kevin Rakin (board member) discloses dealings in 7 companies, chiefly Ocugen, Inc., Oramed Pharmaceuticals Inc. and Clinical Data Inc. We count 65 filings; the first trade dates from 8 August 2006 and the latest from 30 January 2026.

In open-market terms, that means 8 purchases worth €220k on one side and 9 sales worth €767k on the other. The totals do not cover 1 filing with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 22 share grants and 9 option exercises. So far in 2026, the count stands at 1 purchase and no sales.

A typical purchase (the median) is worth €22k.

On 2 February 2026 came the latest disclosure, an open-market purchase for €62k in Elutia Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.